n South African Journal of Psychiatry - Product news

Volume 11, Issue 3
  • ISSN : 1608-9685



Extracted from text ... 100 PAXIL offers quality relief Paxil, a new paroxetine HCl-based psycho-analeptic drug, has been launched into the South African market by GlaxoSmithKline. The schedule-5 drug is indicated for depression, panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social phobia and generalised anxiety disorder (GAD). Navin Singh, medical director at GlaxoSmithKline, says that Paxil is not intended as a replacement for Aropax, which is produced by the same company and will continue to be available, but rather that it should offer an effective, low-cost option for treatment of these conditions. Paroxetine is the only drug of its class currently approved ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error